Transgene signs vaccine manufacturing agreement with IAVI
Transgene releaseStrasbourg, France, December 10, 2002. Transgene (Nasdaq: TRGNY) announced today that it has entered into a collaborative agreement with the International AIDS Vaccine Initiative (IAVI) to manufacture pre-clinical lots of IAVI's constructs for a novel form of vaccine. These constructs, developed at the U.S. National Institute of Allergy and Infectious Disease, consist of modified vaccinia Ankara (MVA) vectors carrying genes of simian immunodeficiency syndrome (SIV) which, in monkeys, is the equivalent of HIV, which causes AIDS in humans. Transgene will manufacture the lots to be used by IAVI in its pre-clinical studies.
—Posted: December 11, 2002
More news headlines: This week | Last week | Search archive